JP2008513479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513479A5 JP2008513479A5 JP2007532511A JP2007532511A JP2008513479A5 JP 2008513479 A5 JP2008513479 A5 JP 2008513479A5 JP 2007532511 A JP2007532511 A JP 2007532511A JP 2007532511 A JP2007532511 A JP 2007532511A JP 2008513479 A5 JP2008513479 A5 JP 2008513479A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- group
- stent
- mammal
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 65
- -1 9-fluoreneacetyl group Chemical group 0.000 claims 44
- 238000000034 method Methods 0.000 claims 42
- 241000124008 Mammalia Species 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 20
- 125000006239 protecting group Chemical group 0.000 claims 19
- 201000001320 Atherosclerosis Diseases 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 9
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 claims 6
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 6
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 230000004968 inflammatory condition Effects 0.000 claims 5
- 238000010255 intramuscular injection Methods 0.000 claims 5
- 239000007927 intramuscular injection Substances 0.000 claims 5
- 239000007928 intraperitoneal injection Substances 0.000 claims 5
- 238000010253 intravenous injection Methods 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 238000010254 subcutaneous injection Methods 0.000 claims 5
- 239000007929 subcutaneous injection Substances 0.000 claims 5
- 150000008574 D-amino acids Chemical class 0.000 claims 4
- 102000007079 Peptide Fragments Human genes 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 3
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 claims 3
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 3
- HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical group C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 claims 3
- DNVJGJUGFFYUPT-UHFFFAOYSA-N 9h-fluorene-9-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)C3=CC=CC=C3C2=C1 DNVJGJUGFFYUPT-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical group 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000006178 methyl benzyl group Chemical group 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 206010048998 Acute phase reaction Diseases 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000004658 acute-phase response Effects 0.000 claims 2
- 229910045601 alloy Inorganic materials 0.000 claims 2
- 239000000956 alloy Substances 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- WJJGAKCAAJOICV-JTQLQIEISA-N (2s)-2-(dimethylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical group CN(C)[C@H](C(O)=O)CC1=CC=C(O)C=C1 WJJGAKCAAJOICV-JTQLQIEISA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108091028732 Concatemer Proteins 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 108010038320 lysylphenylalanine Proteins 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims 1
- 229910001000 nickel titanium Inorganic materials 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920000307 polymer substrate Polymers 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000010935 stainless steel Substances 0.000 claims 1
- 229910001220 stainless steel Inorganic materials 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229910052715 tantalum Inorganic materials 0.000 claims 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61071104P | 2004-09-16 | 2004-09-16 | |
| PCT/US2005/033205 WO2006034056A2 (en) | 2004-09-16 | 2005-09-16 | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513479A JP2008513479A (ja) | 2008-05-01 |
| JP2008513479A5 true JP2008513479A5 (https=) | 2008-11-06 |
Family
ID=36090532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532511A Pending JP2008513479A (ja) | 2004-09-16 | 2005-09-16 | アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060205669A1 (https=) |
| EP (1) | EP1799242A4 (https=) |
| JP (1) | JP2008513479A (https=) |
| CN (1) | CN101065137A (https=) |
| AU (1) | AU2005287004B2 (https=) |
| CA (1) | CA2580501A1 (https=) |
| RU (1) | RU2448977C2 (https=) |
| WO (1) | WO2006034056A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| KR101185609B1 (ko) * | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| KR20070089996A (ko) | 2004-12-06 | 2007-09-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 세동맥의 구조 및 기능의 개선 방법 |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
| AU2007284801A1 (en) | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
| WO2009032702A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| EP2195331B1 (en) | 2007-08-28 | 2013-11-20 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| WO2009093246A2 (en) * | 2008-01-22 | 2009-07-30 | Compugen Ltd. | Novel clusterin derived peptide |
| CA2730042A1 (en) * | 2008-07-07 | 2010-01-14 | Athera Biotechnologies Ab | New therapeutic and diagnostic methods for alzheimer's disease |
| BR112014009686A2 (pt) * | 2011-10-24 | 2018-08-07 | Mannkind Corp | composição analgésica inalável, pó seco e método para tratar dor |
| CN104203262A (zh) * | 2012-02-23 | 2014-12-10 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
| US9539300B2 (en) | 2012-03-31 | 2017-01-10 | The Regents Of The University Of California | Modulating disease through genetic engineering of plants |
| WO2016018665A1 (en) | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| WO2018063796A1 (en) | 2016-09-28 | 2018-04-05 | The Regents Of The University Of California | Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism |
| BR112021002725A2 (pt) * | 2018-08-16 | 2021-07-20 | F. Hoffmann-La Roche Ag | métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para avaliar a eficácia de uma terapia, para identificar um paciente, para monitorar a terapia de anticoagulação e para auxiliar na avaliação da fibrilação atrial, método implementado por computador, kit e uso in vitro |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3767040A (en) * | 1971-03-01 | 1973-10-23 | Minnesota Mining & Mfg | Pressure-sensitive polyurethane adhesives |
| US4155913A (en) * | 1973-02-08 | 1979-05-22 | Hoffmann-La Roche Inc. | Thienotriazolodiazepine derivatives |
| HU185263B (en) * | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| US4643988A (en) * | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| NZ229004A (en) * | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
| US5480869A (en) * | 1990-01-09 | 1996-01-02 | The Regents Of The University Of California | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues |
| AU662885B2 (en) * | 1990-06-07 | 1995-09-21 | Scripps Research Institute, The | APO AI polypeptides, antibodies, and immunoassays |
| DE4101895C1 (https=) * | 1991-01-23 | 1991-12-05 | Forschungszentrum Juelich Gmbh, 5170 Juelich, De | |
| JPH07507554A (ja) * | 1992-06-12 | 1995-08-24 | エヌ・ブイ・イノゲネテイクス・エス・エイ | 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用 |
| US5344822A (en) * | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
| AU672028B2 (en) * | 1992-08-14 | 1996-09-19 | Shino-Test Corporation | Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies |
| JP3401005B2 (ja) * | 1992-12-11 | 2003-04-28 | ユニバーシティ オブ フロリダ | 有害生物の防除のための材料および方法 |
| US5721138A (en) * | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| ATE190065T1 (de) * | 1994-05-12 | 2000-03-15 | Balazs Sarkadi | Stoffe zur aufhebung von arzneimittelresistenzen |
| US5595973A (en) * | 1994-09-12 | 1997-01-21 | Biomeasure Incorporated | Protection of hemopoietic cells during chemotherapy or radiotherapy |
| US6717031B2 (en) * | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US6277826B1 (en) * | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| CN1109047C (zh) * | 1996-03-29 | 2003-05-21 | D·博菲利 | 作为胆固醇和其它脂类摄取抑制剂的两亲分子 |
| US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| US6265382B1 (en) * | 1997-04-11 | 2001-07-24 | Warner-Lambert Company | Dipeptide inhibitors of protein farnesyltransferase |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| DE69805697T3 (de) * | 1997-04-24 | 2006-11-30 | Chemoxal S.A. | Desinfizierende und fungizide Zusammensetzung auf der Basis von Peressigsäure und einem Aminoxid |
| US6018739A (en) * | 1997-05-15 | 2000-01-25 | Raytheon Company | Biometric personnel identification system |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6191151B1 (en) * | 1997-11-12 | 2001-02-20 | Howard M. Zik | Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers |
| US6320017B1 (en) * | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US20030077641A1 (en) * | 1998-03-11 | 2003-04-24 | Laskowitz Daniel T. | Methods of suppressing microglial activation and systemic inflammatory responses |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| US6846636B1 (en) * | 1998-05-15 | 2005-01-25 | American National Red Cross | Methods and compositions for HDL holoparticle uptake receptor |
| US6172071B1 (en) * | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| US6228989B1 (en) * | 1998-11-13 | 2001-05-08 | The Regents Of The University Of California | Peptide substrates phosphorylated by P21-activated protein kinase |
| WO2000034469A1 (en) * | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| GB9911689D0 (en) * | 1999-05-19 | 1999-07-21 | Medical Res Council | Refolding method |
| US6727063B1 (en) * | 1999-09-10 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Single nucleotide polymorphisms in genes |
| EP1226231A4 (en) * | 1999-11-02 | 2003-07-09 | Human Genome Sciences Inc | 19 HUMANE SECRETIED PROTEINS |
| GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US6596544B1 (en) * | 2000-03-31 | 2003-07-22 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US6444681B1 (en) * | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| US20020068729A1 (en) * | 2000-07-13 | 2002-06-06 | Alteon, Inc. | Method for treating fibrotic diseases or other indications IC |
| AU7705601A (en) * | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7166578B2 (en) * | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US6982348B2 (en) * | 2001-01-26 | 2006-01-03 | Takeda Pharmaceutical Company Limited | Aminoethanol derivatives |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| US20030096737A1 (en) * | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| US20030125260A1 (en) * | 2001-10-31 | 2003-07-03 | Fortuna Haviv | Tetra-and pentapeptides having antiangiogenic activity |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| JP4032857B2 (ja) * | 2002-07-24 | 2008-01-16 | ソニー株式会社 | タッチパネル用のガラス基板、タッチパネル及び携帯端末 |
| AU2003291206A1 (en) * | 2002-12-04 | 2004-06-23 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| EP1594437A2 (en) * | 2003-02-04 | 2005-11-16 | University of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| US20050070996A1 (en) * | 2003-04-08 | 2005-03-31 | Dinh Thomas Q. | Drug-eluting stent for controlled drug delivery |
| US6936961B2 (en) * | 2003-05-13 | 2005-08-30 | Eastman Kodak Company | Cascaded organic electroluminescent device having connecting units with N-type and P-type organic layers |
| US7291590B2 (en) * | 2003-06-12 | 2007-11-06 | Queen's University At Kingston | Compositions and methods for treating atherosclerosis |
| ES2381551T3 (es) * | 2003-12-05 | 2012-05-29 | The Cleveland Clinic Foundation | Marcadores de riesgo para enfermedad cardiovascular |
| KR101185609B1 (ko) * | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| KR20070089996A (ko) * | 2004-12-06 | 2007-09-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 세동맥의 구조 및 기능의 개선 방법 |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
-
2005
- 2005-09-16 AU AU2005287004A patent/AU2005287004B2/en not_active Ceased
- 2005-09-16 JP JP2007532511A patent/JP2008513479A/ja active Pending
- 2005-09-16 EP EP05803724A patent/EP1799242A4/en not_active Withdrawn
- 2005-09-16 US US11/229,042 patent/US20060205669A1/en not_active Abandoned
- 2005-09-16 CA CA002580501A patent/CA2580501A1/en not_active Abandoned
- 2005-09-16 CN CNA2005800392242A patent/CN101065137A/zh active Pending
- 2005-09-16 WO PCT/US2005/033205 patent/WO2006034056A2/en not_active Ceased
- 2005-09-16 RU RU2007114144/04A patent/RU2448977C2/ru not_active IP Right Cessation
-
2011
- 2011-06-08 US US13/156,269 patent/US20120004720A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513479A5 (https=) | ||
| RU2007114144A (ru) | Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид (варианты), содержащий его фармацевтический препарат и способ его применения (варианты), и способ его синтеза | |
| TWI339208B (en) | Glp-1 analogues | |
| JP2004506693A5 (https=) | ||
| TW593338B (en) | Analogues of GLP-1 | |
| JP3694332B2 (ja) | 新規環状ペプチド | |
| JP2016515620A5 (https=) | ||
| AU2007287549B2 (en) | Galenic formulations of aliskiren | |
| CA2718348A1 (en) | Orally administered peptides to ameliorate atherosclerosis | |
| RU2006107605A (ru) | Пептид (варианты), пара аминокислот, снижающие интенсивность по меньшей мере одного симптома воспалительного состояния, фармацевтическая композиция (варианты), лекарственное средство и фармацевтический набор на их основе | |
| TW200306826A (en) | Drug delivery systems for the prevention and treatment of vascular diseases | |
| WO2011156453A4 (en) | Therapeutic peptides | |
| WO2012014214A2 (en) | Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension | |
| DK2957292T3 (en) | VITILIGOTERAPHY | |
| JP2008522980A5 (https=) | ||
| CN101983068B (zh) | N末端和c末端取代的人gh-rh拮抗类似物 | |
| JP2000510102A (ja) | 環状接着阻害剤 | |
| CN115737607B (zh) | 含有阿戈美拉汀的经粘膜治疗系统 | |
| EP4177263A1 (en) | Novel polypeptide and therapeutic use thereof | |
| JPH05503103A (ja) | 障害を受けた組織における血管漏洩を抑制する抗炎症ペプチド及びその組織の治療方法 | |
| JP2009500045A5 (https=) | ||
| ES2393335T3 (es) | Análogos de GLP-1 | |
| EP2317986A2 (en) | System for the colon delivery of drugs subject to enzyme degradation and/or poorly absorbed in the gastrointestinal tract | |
| Goldschmidt et al. | Compound cardiac toxicity of oral erythromycin and verapamil | |
| JP5421257B2 (ja) | プラスミノーゲン活性化因子阻害物質１由来のペプチドおよびその使用 |